Keratoconus is an eye condition where the normally round, dome-shaped cornea (the clear front surface of the eye) gradually thins and bulges outward into a cone shape. This irregular shape can distort vision and make everyday tasks like reading or driving more difficult.
Symptoms usually begin in the late teens to early 20s and may progress over 10–20 years.
Keratoconus is a progressive, non-inflammatory eye disease where the clear, dome-shaped outer window of the eye (the cornea) gradually thins and bulges outward into an irregular cone shape.
Common early symptoms include:
No, keratoconus does not cause total black-out blindness because it only alters the cornea and does not damage the optic nerve or retina. However, if left untreated, the progressive thinning and cone bulging can cause severe irregular astigmatism and apical corneal scarring, resulting in significant visual impairment (often classified as "legal blindness") that cannot be corrected with regular spectacles.
The exact cause is multifactorial, involving genetic predisposition, environmental triggers, and cellular enzyme imbalances that weaken corneal collagen fibers:
No. LASIK is strictly contraindicated for anyone with keratoconus or even subclinical/forme fruste keratoconus. LASIK involves slicing a corneal flap and removing underlying tissue, which further weakens an already structurally compromised cornea and can trigger severe, rapid corneal ectasia (uncontrolled bulging). Patients with keratoconus require stabilizing treatments like C3R (cross-linking) or specialty rigid/scleral lenses rather than laser vision correction.
Corneal Collagen Cross-Linking (C3R / CXL) is a minimally invasive procedure designed to halt the progression of keratoconus. During the treatment, riboflavin (Vitamin B2) drops are applied to the cornea and activated with calibrated UV-A light. This photo-chemical reaction creates new chemical bonds (cross-links) between adjacent collagen fibrils, stiffening and strengthening the corneal structure to prevent further cone bulging.
C3R is primarily a stabilizing procedure, not a refractive cure. Its primary goal is to arrest disease progression and prevent the need for a future corneal transplant. While many patients experience mild flattening of the cone and slight visual improvement, most patients still require optical rehabilitation after C3R—such as specialty scleral contact lenses or custom rigid gas-permeable (RGP) lenses—to achieve crisp, sharp vision.
Scleral lenses are large-diameter, rigid gas-permeable lenses designed specifically for irregular corneas. Unlike regular contact lenses that rest directly on the sensitive cornea, scleral lenses:
Intacs are microscopic, clear, crescent-shaped polymer inserts surgically placed within the deep middle layers (stroma) of the cornea. By acting like structural architectural supports, they flatten the central cone, reshape irregular curvature, and reduce refractive error. Intacs are often combined with C3R cross-linking to both reshape and biomechanically stabilize the cornea simultaneously.
Corneal transplant surgery is considered an advanced-stage option (required in fewer than 10–15% of cases) when:
Deep Anterior Lamellar Keratoplasty (DALK) is the preferred partial-thickness transplant technique because it preserves the patient's healthy inner endothelial layer, virtually eliminating the risk of endothelial graft rejection.
Routine eye exams and standard refraction cannot detect early-stage keratoconus. At ARC Eye Centre, diagnosis is established using high-precision diagnostics:
ARC Eye and Retina Centre delivers advanced eye and retina care with expert doctors, modern technology, and compassionate patient-focused treatment.